Sullivan EK - Search Results

1

Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist.

Hellberg MR, McLaughlin MA, Sharif NA, DeSantis L, Dean TR, Kyba EP, Bishop JE, Klimko PG, Zinke PW, Selliah RD, Barnes G, DeFaller J, Kothe A, Landry T, Sullivan EK, Andrew R, Davis AA, Silver L, Bergamini MV, Robertson S, Weiner AL, Sallee VL. Hellberg MR, et al. Among authors: sullivan ek. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S13-33. doi: 10.1016/s0039-6257(02)00293-x. Surv Ophthalmol. 2002. PMID: 12204698

2

Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial.

Fellman RL, Sullivan EK, Ratliff M, Silver LH, Whitson JT, Turner FD, Weiner AL, Davis AA; Travoprost Study Group. Fellman RL, et al. Among authors: sullivan ek. Ophthalmology. 2002 May;109(5):998-1008. doi: 10.1016/s0161-6420(02)01010-2. Ophthalmology. 2002. PMID: 11986110 Clinical Trial.

3

Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension.

Netland PA, Robertson SM, Sullivan EK, Silver L, Bergamini MV, Krueger S, Weiner AL, Davis AA; Travoprost Study Groups. Netland PA, et al. Among authors: sullivan ek. Adv Ther. 2003 May-Jun;20(3):149-63. doi: 10.1007/BF02850202. Adv Ther. 2003. PMID: 12956257 Clinical Trial.

4

Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.

Schuman JS, Katz GJ, Lewis RA, Henry JC, Mallick S, Wells DT, Sullivan EK, Landry TA, Bergamini MV, Robertson SM. Schuman JS, et al. Among authors: sullivan ek. Am J Ophthalmol. 2005 Aug;140(2):242-50. doi: 10.1016/j.ajo.2005.02.058. Am J Ophthalmol. 2005. PMID: 16086946 Clinical Trial.

5

The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1.

Whitson JT, Ochsner KI, Moster MR, Sullivan EK, Andrew RM, Silver LH, Wells DT, James JE, Bosworth CF, Dickerson JE, Landry TA, Bergamini MV; Brimonidine 0.15% Study Group. Whitson JT, et al. Among authors: sullivan ek. Ophthalmology. 2006 Aug;113(8):1333-9. doi: 10.1016/j.ophtha.2006.03.025. Ophthalmology. 2006. PMID: 16877072 Clinical Trial.

6

Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.

Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA; Travoprost Study Group. Netland PA, et al. Among authors: sullivan ek. Am J Ophthalmol. 2001 Oct;132(4):472-84. doi: 10.1016/s0002-9394(01)01177-1. Am J Ophthalmol. 2001. PMID: 11589866 Clinical Trial.

7

Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy.

Lewis RA, Katz GJ, Weiss MJ, Landry TA, Dickerson JE, James JE, Hua SY, Sullivan EK, Montgomery DB, Wells DT, Bergamini MV; Travoprost BAC-free Study Group. Lewis RA, et al. Among authors: sullivan ek. J Glaucoma. 2007 Jan;16(1):98-103. doi: 10.1097/01.ijg.0000212274.50229.c6. J Glaucoma. 2007. PMID: 17224758 Clinical Trial.

8

Pooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5%.

Gross RL, Sullivan EK, Wells DT, Mallick S, Landry TA, Bergamini MV. Gross RL, et al. Among authors: sullivan ek. Clin Ophthalmol. 2007 Sep;1(3):317-22. Clin Ophthalmol. 2007. PMID: 19668487 Free PMC article.

9

Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension.

Goldberg I, Cunha-Vaz J, Jakobsen JE, Nordmann JP, Trost E, Sullivan EK; International Travoprost Study Group. Goldberg I, et al. Among authors: sullivan ek. J Glaucoma. 2001 Oct;10(5):414-22. doi: 10.1097/00061198-200110000-00010. J Glaucoma. 2001. PMID: 11711841 Clinical Trial.

10

Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration.

Slakter JS, Bochow TW, D'Amico DJ, Marks B, Jerdan J, Sullivan EK, Robertson SM, Slakter JS, Sullins G, Zilliox P; Anecortave Acetate Clinical Study Group. Slakter JS, et al. Among authors: sullivan ek. Ophthalmology. 2006 Jan;113(1):3-13. doi: 10.1016/j.ophtha.2005.10.019. Epub 2005 Dec 20. Ophthalmology. 2006. PMID: 16368146 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

69 results

Search Page

Filters